vs
Ultragenyx Pharmaceutical Inc.（RARE）与STURM RUGER & CO INC（RGR）财务数据对比。点击上方公司名可切换其他公司
Ultragenyx Pharmaceutical Inc.的季度营收约是STURM RUGER & CO INC的1.4倍（$207.3M vs $151.1M），Ultragenyx Pharmaceutical Inc.同比增速更快（25.9% vs 3.6%），STURM RUGER & CO INC自由现金流更多（$12.3M vs $-100.8M），过去两年Ultragenyx Pharmaceutical Inc.的营收复合增速更高（38.0% vs 5.1%）
Ultragenyx Pharmaceutical Inc.是一家总部位于美国的生物制药企业，专注于研发罕见病和超罕见遗传病的创新治疗方案，这类疾病目前大多无获批疗法，存在大量未被满足的临床需求。公司覆盖生物制剂、小分子药物、基因疗法、反义寡核苷酸及mRNA等多种药物技术平台，研发管线涵盖骨骼、内分泌、代谢、肌肉及中枢神经系统疾病领域。
鲁格公司（Ruger）是总部位于美国康涅狄格州绍斯波特的枪械制造企业，除总部外，还在新罕布什尔州纽波特、北卡罗来纳州梅约丹以及亚利桑那州普雷斯科特设有生产工厂。公司由亚历山大·麦考密克·斯特姆与威廉·B·鲁格于1949年共同创立，自1969年起公开上市交易。
RARE vs RGR — 直观对比
损益表 — Q4 FY2025 vs Q4 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $207.3M | $151.1M |
| 净利润 | $-128.6M | — |
| 毛利率 | — | 17.8% |
| 营业利润率 | -54.7% | 2.3% |
| 净利率 | -62.0% | — |
| 营收同比 | 25.9% | 3.6% |
| 净利润同比 | 3.5% | — |
| 每股收益（稀释后） | $-1.28 | $0.22 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
| Q4 25 | $207.3M | $151.1M | ||
| Q3 25 | $159.9M | $126.8M | ||
| Q2 25 | $166.5M | $132.5M | ||
| Q1 25 | $139.3M | $135.7M | ||
| Q4 24 | $164.6M | $145.8M | ||
| Q3 24 | $139.5M | $122.3M | ||
| Q2 24 | $147.0M | $130.8M | ||
| Q1 24 | $108.8M | $136.8M |
| Q4 25 | $-128.6M | — | ||
| Q3 25 | $-180.4M | $1.6M | ||
| Q2 25 | $-115.0M | $-17.2M | ||
| Q1 25 | $-151.1M | $7.8M | ||
| Q4 24 | $-133.2M | — | ||
| Q3 24 | $-133.5M | $4.7M | ||
| Q2 24 | $-131.6M | $8.3M | ||
| Q1 24 | $-170.7M | $7.1M |
| Q4 25 | — | 17.8% | ||
| Q3 25 | — | 15.1% | ||
| Q2 25 | — | 3.9% | ||
| Q1 25 | — | 22.0% | ||
| Q4 24 | — | 22.8% | ||
| Q3 24 | — | 18.5% | ||
| Q2 24 | — | 22.3% | ||
| Q1 24 | — | 21.5% |
| Q4 25 | -54.7% | 2.3% | ||
| Q3 25 | -106.9% | -2.7% | ||
| Q2 25 | -64.8% | -15.6% | ||
| Q1 25 | -102.6% | 6.2% | ||
| Q4 24 | -74.3% | 7.8% | ||
| Q3 24 | -94.6% | 3.1% | ||
| Q2 24 | -79.1% | 6.9% | ||
| Q1 24 | -151.9% | 5.5% |
| Q4 25 | -62.0% | — | ||
| Q3 25 | -112.8% | 1.2% | ||
| Q2 25 | -69.0% | -13.0% | ||
| Q1 25 | -108.5% | 5.7% | ||
| Q4 24 | -80.9% | — | ||
| Q3 24 | -95.7% | 3.9% | ||
| Q2 24 | -89.5% | 6.3% | ||
| Q1 24 | -156.8% | 5.2% |
| Q4 25 | $-1.28 | $0.22 | ||
| Q3 25 | $-1.81 | $0.10 | ||
| Q2 25 | $-1.17 | $-1.05 | ||
| Q1 25 | $-1.57 | $0.46 | ||
| Q4 24 | $-1.34 | $0.62 | ||
| Q3 24 | $-1.40 | $0.28 | ||
| Q2 24 | $-1.52 | $0.47 | ||
| Q1 24 | $-2.03 | $0.40 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $421.0M | $92.5M |
| 总债务越低越好 | — | — |
| 股东权益账面价值 | $-80.0M | $283.8M |
| 总资产 | $1.5B | $342.0M |
| 负债/权益比越低杠杆越低 | — | — |
8季度趋势，按日历期对齐
| Q4 25 | $421.0M | $92.5M | ||
| Q3 25 | $202.5M | $80.8M | ||
| Q2 25 | $176.3M | $101.4M | ||
| Q1 25 | $127.1M | $108.3M | ||
| Q4 24 | $174.0M | $105.5M | ||
| Q3 24 | $150.6M | $96.0M | ||
| Q2 24 | $480.7M | $105.6M | ||
| Q1 24 | $112.3M | $115.3M |
| Q4 25 | $-80.0M | $283.8M | ||
| Q3 25 | $9.2M | $279.6M | ||
| Q2 25 | $151.3M | $289.3M | ||
| Q1 25 | $144.2M | $321.5M | ||
| Q4 24 | $255.0M | $319.6M | ||
| Q3 24 | $346.8M | $314.9M | ||
| Q2 24 | $432.4M | $321.5M | ||
| Q1 24 | $140.3M | $332.0M |
| Q4 25 | $1.5B | $342.0M | ||
| Q3 25 | $1.2B | $342.3M | ||
| Q2 25 | $1.3B | $349.5M | ||
| Q1 25 | $1.3B | $379.0M | ||
| Q4 24 | $1.5B | $384.0M | ||
| Q3 24 | $1.5B | $373.5M | ||
| Q2 24 | $1.6B | $376.7M | ||
| Q1 24 | $1.3B | $385.0M |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $-99.8M | $15.5M |
| 自由现金流经营现金流 - 资本支出 | $-100.8M | $12.3M |
| 自由现金流率自由现金流/营收 | -48.6% | 8.2% |
| 资本支出强度资本支出/营收 | 0.5% | 2.1% |
| 现金转化率经营现金流/净利润 | — | — |
| 过去12个月自由现金流最近4个季度 | $-472.0M | $38.5M |
8季度趋势，按日历期对齐
| Q4 25 | $-99.8M | $15.5M | ||
| Q3 25 | $-91.4M | $12.9M | ||
| Q2 25 | $-108.3M | $14.7M | ||
| Q1 25 | $-166.5M | $11.1M | ||
| Q4 24 | $-79.3M | $20.0M | ||
| Q3 24 | $-67.0M | $9.4M | ||
| Q2 24 | $-77.0M | $18.7M | ||
| Q1 24 | $-190.7M | $7.3M |
| Q4 25 | $-100.8M | $12.3M | ||
| Q3 25 | $-92.7M | $7.0M | ||
| Q2 25 | $-110.7M | $9.1M | ||
| Q1 25 | $-167.8M | $10.0M | ||
| Q4 24 | $-79.5M | $16.4M | ||
| Q3 24 | $-68.6M | $2.6M | ||
| Q2 24 | $-79.0M | $10.1M | ||
| Q1 24 | $-193.9M | $5.6M |
| Q4 25 | -48.6% | 8.2% | ||
| Q3 25 | -58.0% | 5.5% | ||
| Q2 25 | -66.5% | 6.9% | ||
| Q1 25 | -120.5% | 7.4% | ||
| Q4 24 | -48.3% | 11.2% | ||
| Q3 24 | -49.2% | 2.1% | ||
| Q2 24 | -53.7% | 7.7% | ||
| Q1 24 | -178.2% | 4.1% |
| Q4 25 | 0.5% | 2.1% | ||
| Q3 25 | 0.8% | 4.6% | ||
| Q2 25 | 1.5% | 4.2% | ||
| Q1 25 | 1.0% | 0.8% | ||
| Q4 24 | 0.1% | 2.5% | ||
| Q3 24 | 1.2% | 5.5% | ||
| Q2 24 | 1.4% | 6.6% | ||
| Q1 24 | 3.0% | 1.3% |
| Q4 25 | — | — | ||
| Q3 25 | — | 8.15× | ||
| Q2 25 | — | — | ||
| Q1 25 | — | 1.43× | ||
| Q4 24 | — | — | ||
| Q3 24 | — | 1.98× | ||
| Q2 24 | — | 2.27× | ||
| Q1 24 | — | 1.04× |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
RARE
| Royalty | $105.6M | 51% |
| Products | $101.7M | 49% |
RGR
| Firearms | $150.6M | 100% |
| Castings | $7.3M | 5% |
